Morepen Laboratories Limited (MOREPENLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹32.8B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +30.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹34.09 – ₹65.87 · fair‑value band ₹22.08 – ₹36.79 · the ₹59.79 price screens above the ₹29.44 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Morepen Laboratories Limited (MOREPENLAB) currently trades at ₹59.79, while our model-based Fair Value estimate is ₹29.44 — implying the stock looks roughly 50.8% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Morepen Laboratories Limited generated revenue of ₹18.1B at a net margin of 5.3%. Revenue grew 4.0% year over year. It earns a return on equity of 7.9%. Net debt stands at ₹1.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Morepen Laboratories Limited reported revenue of ₹18.1B in FY2026 versus ₹15.4B in FY2022, a compound +4.0%/yr. Reported net income was ₹949M in FY2026, compounding −1.7%/yr from FY2022.
Is MOREPENLAB fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Morepen Laboratories Limited (MOREPENLAB) undervalued?
What is the fair value of MOREPENLAB?
What is the quality score of MOREPENLAB?
What is the revenue of Morepen Laboratories Limited (MOREPENLAB)?
What is the net profit margin of MOREPENLAB?
Does Morepen Laboratories Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.